126 related articles for article (PubMed ID: 30224542)
21. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
22. Genetic progression model for head and neck cancer: implications for field cancerization.
Califano J; van der Riet P; Westra W; Nawroz H; Clayman G; Piantadosi S; Corio R; Lee D; Greenberg B; Koch W; Sidransky D
Cancer Res; 1996 Jun; 56(11):2488-92. PubMed ID: 8653682
[TBL] [Abstract][Full Text] [Related]
23. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck.
Westra WH; Taube JM; Poeta ML; Begum S; Sidransky D; Koch WM
Clin Cancer Res; 2008 Jan; 14(2):366-9. PubMed ID: 18223210
[TBL] [Abstract][Full Text] [Related]
24. Visualization of the timing of gene amplification during multistep head and neck tumorigenesis.
Roh HJ; Shin DM; Lee JS; Ro JY; Tainsky MA; Hong WK; Hittelman WN
Cancer Res; 2000 Nov; 60(22):6496-502. PubMed ID: 11103819
[TBL] [Abstract][Full Text] [Related]
25. Status of primary tumour surgical margins in squamous head and neck cancer: prognostic implications.
Bradley PJ; MacLennan K; Brakenhoff RH; Leemans CR
Curr Opin Otolaryngol Head Neck Surg; 2007 Apr; 15(2):74-81. PubMed ID: 17413406
[TBL] [Abstract][Full Text] [Related]
26. Intratumor genetic heterogeneity and head and neck cancer relapse.
Pierik AS; Poell JB; Brink A; Stigter-van Walsum M; de Roest RH; Poli T; Yaromin A; Lambin P; Leemans CR; Brakenhoff RH
Radiother Oncol; 2024 Feb; 191():110087. PubMed ID: 38185257
[TBL] [Abstract][Full Text] [Related]
27. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
28. Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells.
Summerer I; Hess J; Pitea A; Unger K; Hieber L; Selmansberger M; Lauber K; Zitzelsberger H
BMC Genomics; 2015 Sep; 16(1):654. PubMed ID: 26328888
[TBL] [Abstract][Full Text] [Related]
29. Combinational chromosomal aneuploidies and HPV status for prediction of head and neck squamous cell carcinoma prognosis in biopsies and cytological preparations.
Wemmert S; Linxweiler M; Lerner C; Bochen F; Kulas P; Linxweiler J; Smola S; Urbschat S; Wagenpfeil S; Schick B
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1129-1141. PubMed ID: 29560516
[TBL] [Abstract][Full Text] [Related]
30. Second field tumors: a new opportunity for cancer prevention?
Braakhuis BJ; Brakenhoff RH; Leemans CR
Oncologist; 2005 Aug; 10(7):493-500. PubMed ID: 16079316
[TBL] [Abstract][Full Text] [Related]
31. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia.
Kresty LA; Mallery SR; Knobloch TJ; Song H; Lloyd M; Casto BC; Weghorst CM
Cancer Res; 2002 Sep; 62(18):5295-300. PubMed ID: 12234999
[TBL] [Abstract][Full Text] [Related]
32. Comparison of p16(INK4a) expression with p53 alterations in head and neck cancer by tissue microarray analysis.
Karsai S; Abel U; Roesch-Ely M; Affolter A; Hofele C; Joos S; Plinkert PK; Bosch FX
J Pathol; 2007 Feb; 211(3):314-22. PubMed ID: 17152048
[TBL] [Abstract][Full Text] [Related]
33. The p53 status of cultured human premalignant oral keratinocytes.
Burns JE; Clark LJ; Yeudall WA; Mitchell R; Mackenzie K; Chang SE; Parkinson EK
Br J Cancer; 1994 Oct; 70(4):591-5. PubMed ID: 7917902
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression.
Hasina R; Hulett K; Bicciato S; Di Bello C; Petruzzelli GJ; Lingen MW
Cancer Res; 2003 Feb; 63(3):555-9. PubMed ID: 12566295
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
36. Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications.
van Harten AM; Brakenhoff RH
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204886
[TBL] [Abstract][Full Text] [Related]
37. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study.
Tabor MP; Brakenhoff RH; Ruijter-Schippers HJ; Kummer JA; Leemans CR; Braakhuis BJ
Clin Cancer Res; 2004 Jun; 10(11):3607-13. PubMed ID: 15173066
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of p53 protein is common in premalignant head and neck lesions.
Pavelic ZP; Li YQ; Stambrook PJ; McDonald JS; Munck-Wikland E; Pavelic K; Dacic S; Danilovic Z; Pavelic L; Mugge RE
Anticancer Res; 1994; 14(5B):2259-66. PubMed ID: 7840533
[TBL] [Abstract][Full Text] [Related]
39. Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma.
Mafune A; Hama T; Suda T; Suzuki Y; Ikegami M; Sakanashi C; Imai S; Nakashima A; Yokoo T; Wada K; Kojima H; Urashima M
BMC Cancer; 2015 Mar; 15():205. PubMed ID: 25886176
[TBL] [Abstract][Full Text] [Related]
40. Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas.
Cabanillas R; Astudillo A; Valle M; de la Rosa J; Álvarez R; Durán NS; Cadiñanos J
Head Neck; 2013 Mar; 35(3):E80-4. PubMed ID: 22083977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
